Avanir To Pay $108M Over Nuedexta Drug Kickback Scheme

By Hailey Konnath (September 26, 2019, 9:26 PM EDT) -- Drugmaker Avanir Pharmaceuticals has agreed to shell out more than $108 million in criminal penalties, forfeiture and civil damages for an alleged kickback scheme that involved the company paying physicians to prescribe its drug Nuedexta, the U.S. Department of Justice announced Thursday.

Two physicians and two former Avanir Pharmaceuticals sales representatives have been indicted in an alleged kickback scheme, the U.S. Department of Justice said. (AP) On top of the kickbacks, the company also used false and misleading advertising to coerce long-term care facilities to use the drug to treat conditions that had not been approved by the U.S. Food and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!